



## SERUM URIC ACID LEVELS IN CHRONIC OBSTRUCTIVE LUNG DISEASE PATIENTS

Arifath Gopinath<sup>1\*</sup>, Lalitha Shanmugam<sup>2</sup>

<sup>1</sup>Associate Professor of Physiology, Melmaruvathur Adhiparasakthi Institute of Medical Sciences and Research Institute, Melmaruvathur, Tamilnadu, India

<sup>2</sup>Assistant Professor of Physiology, Melmaruvathur Adhiparasakthi Institute of Medical Sciences and Research Institute, Melmaruvathur, Tamilnadu, India

### ABSTRACT

Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality worldwide and results in an economic and social burden that is both substantial and increasing. This study was done to measure serum uric acid levels in chronic obstructive pulmonary disease patients. Serum uric acid, the final product of purine degradation, has been shown to be increased in the hypoxic state as well as in systemic inflammation including patients with chronic obstructive pulmonary disease (COPD). Elevated serum uric acid level may be a noninvasive indicator for COPD severity and hypoxemia in stable COPD patients. Therefore, it is suggested to assess serum UA as an important and additional parameter for COPD patients.

**Key words:** COPD, Uric Acid, hypoxia, Spirometry.

### INTRODUCTION

Serum uric acid is increased in respiratory disease, especially in the presence of hypoxia and systemic inflammation. We evaluated serum uric acid as a biomarker for prediction of mortality and future acute exacerbation of chronic obstructive pulmonary disease (AECOPD). Chronic obstructive pulmonary disease (COPD) is one of the leading causes of morbidity and mortality with increasing prevalence worldwide [1]. An acute exacerbation of COPD (AECOPD) is characterised by a significant change in symptoms that is acute in onset and may warrant a change in regular medication [1]. Some COPD patients are particularly susceptible to exacerbations, and this has a negative impact on survival [2]. Serum uric acid is the final product of purine degradation [3], which increases significantly during hypoxia [4]. Elevated uric acid levels have been associated with the presence of systemic inflammation [5] and increased cardiovascular risk [6]. In this context, increased levels of uric acid have been shown in respiratory

disorders, including obstructive sleep apnoea [7] and pulmonary hypertension [8]. In COPD, cigarette smoke induces oxidative stress and lung inflammation, resulting in lung tissue damage and decline of pulmonary function [1].

Lung functions are deranged because of damage to lung tissues induced by oxidants and inflammation. This derangement reduces oxygen intake leading to tissue hypoxia causing hypercapnia. Hyperuricemia is defined as serum uric acid (UA) levels  $>7.1\text{mg/dL}$  in males or  $>6.1\text{mg/dL}$  in females. In comparison to normal individuals, hyperuricemics have more inflammation and oxidative stress injuries. Pro-inflammatory effect of UA is more profound in those with high serum UA levels. Our study aim is to assess whether the presence of higher values of serum UA is associated with changes in clinical and functional characteristics in patients with chronic obstructive pulmonary disease (COPD).

Corresponding Author:- **Dr.Arifath Gopinath** Email:- drpebyreddy@gmail.com

## Materials and methods

The study was conducted after having obtained permission from the Institutional Ethics committee, Madras Medical College, Chennai, India. 110 stable COPD patients in the age group 35-70 years (mean age 51.5 yrs) who attended at Melmaruvathur Adhiparasakthi Institute of Medical Sciences and Research Institute, Melmaruvathur were included in this study.

Spirometric parameters like FVC and FEV were measured using standard techniques with Spirometer Easy. Spirometry was done without the administration of any bronchodilator. The highest value out of three FVC maneuvers by each subject was used in the analysis. Percent predicted values for spirometric parameters are presented as FEV % predicted and FVC % predicted. Subjects with FEV /FVC <70% were identified as having airflow limitation (COPD). According to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria, subjects with airflow limitation and FEV1 % predicted  $\geq 80$  were identified as having mild airflow limitation, those with FEV % predicted between 50 and 80 were defined as having moderate airflow limitation, and those with FEV % predicted <50 were defined as having severe airflow limitation. Of the total 110 cases, 52 were mild, 42 were moderate and 16 were severe COPD patients. 74 age and sex matched subjects were included as controls (mean age 48.7 yrs). Clinical assessment included detailed physical examination, information regarding smoking history, biomass exposure and accompanying diseases were elicited from both cases and control groups.

Exclusion criteria for the present study includes patients with history of pulmonary tuberculosis, asthma, coronary artery disease, renal disease, liver disease, diabetes mellitus, cancer and patients on chemotherapy and radiotherapy. Venous blood samples were drawn from controls and COPD patients. Renal function tests, liver function tests, uric acid and electrolytes and serum uric acid was analysed by using Siemens fully automated analyser.

## Statistical Analysis

Clinical characteristics of the study population were compared using Chi square test and Student's t-test. p - Value of < 0.05 were considered statistically significant. Comparison of serum uric acid levels between patients with COPD and controls were done using Student's Unpaired t-test. Comparison of serum uric acid levels between various stages of patients with COPD was performed using ANOVA.

## Results

**Table no: 1** Clinical characteristics of the study population

**Table no: 2** Serum uric acid levels in controls and COPD patients

**Table-3** Comparison of serum uric acid levels between various stages of patients with COPD

## Discussion:

Uric acid levels have been previously associated with clinical and functional characteristics in patients with COPD in cross-sectional studies [9, 10]. UA is the end-product of purine degradation. Excessive intake of foods containing purine bases, alcohol consumption, renal dysfunction and genetic disorders of purine metabolism, such as hypoxanthine-guanine phosphoribosyl transferase deficiency (Lesch-Nyhan syndrome) and adenine phosphoribosyl transferase deficiency, result in elevation of serum UA levels. [11-14] In addition, other demographic and clinical factors, such as gender, BMI, smoking index, and serum glucose levels, are known to be associated with increased serum levels of UA. [15] Therefore, careful consideration of these factors is required when assessing the relationship between pulmonary function and UA levels. Tissue hypoxia has been reported to induce the degradation of adenosine. [16] This results in the release of purine intermediates and end products of purine catabolism, such as uric acid (UA). [17] Elevation of serum UA (sUA) levels has been observed in hypoxic subjects, including patients with COPD. [18]

Tissue hypoxia has been reported to induce the degradation of [19] adenosine. This results in the release of purine intermediates and [20] end products of purine catabolism, such as uric acid (UA). Elevation of serum UA (sUA) levels has been observed in hypoxic subjects, [21] including patients with COPD. UA is a biomarker of xanthine oxidase activity, which is known to be an important source of reactive oxygen species. [22] Several investigators have reported that elevated UA levels were associated with worsening of cardiovascular disease, heart failure and COPD. [23]

As a routine laboratory index, serum uric acid is frequently used to evaluate the renal function of patients and it has also been shown to be the main contributor to the antioxidant capacity. Previous studies demonstrated that uric acid could be an independent biomarker of impaired prognosis for some extra pulmonary diseases (such as congestive heart failure and metabolic syndrome), which may be associated with impaired oxidative metabolism. [24-26] Furthermore, the association between the levels of serum uric acid and the severity of pulmonary disease has also drawn more and more attention. [27-29]

Our findings suggest that systemic UA levels are associated with oxidative stress and inflammation in vivo. UA [30] activates leukocytes through the NALP3 inflammasome. Activated leukocytes express selectins and adhere to endothelial cells, where they secrete various pro-inflammatory cytokines and chemical mediators, resulting in vessel wall damage and atherosclerosis. These findings suggest that systemic UA levels are associated with oxidative stress and inflammation in vivo. UA activates leukocytes through the NALP3 inflammasome. [16] Activated leukocytes express selectins and adhere to

endothelial cells, where they secrete various pro-inflammatory cytokines and chemical mediators, resulting in vessel wall damage and atherosclerosis. Possible explanations for the association between elevated sUA levels and pulmonary function includes 1) hypoxia due to impaired pulmonary function leading to purine catabolism, 2) impaired pulmonary function inducing pulmonary hypertension and resulting in the elevation of sUA levels, 3) Toxins in cigarette smoke causes oxidative stress in the alveolar spaces of the lungs. This oxidative stress induces lung inflammation contributing to the pathogenesis of chronic respiratory diseases, such as COPD and pulmonary fibrosis.[31] While assessing the relationship between pulmonary function and UA levels, certain factors should be considered carefully. It is a known fact that UA is the end-product of purine degradation. Alcohol consumption, excessive in takeoff foods containing purine bases, renal dysfunction and genetic disorders of purine metabolism, such as hypoxanthine-guanine phosphoribosyl transferase deficiency (Lesch-Nyhan syndrome) and adenine phosphoribosyl transferase deficiency are the

factors which increases serum UA levels[31]. The association between serum uric acid levels and COPD. This current meta-analysis demonstrated that serum uric acid levels were significantly higher in stable COPD patients than healthy control subjects, and there was a relationship between the levels of serum uric acid and the severity of the airflow limitation in stable COPD patients.

#### Conclusion:

Serum uric acid is a widely and rapidly available, easy to interpret, low-cost. This low-cost biomarker may be useful in the identification of high-risk chronic obstructive pulmonary disease patients that could benefit from intensive management. Elevated serum uric acid level may serve as a non invasive indicator for COPD severity and hypoxemia in stable COPD patients. There is a need to evaluate serum UA levels as an additional parameter for predicting outcome in COPD patients. Biomarker, suggest a possible role for serum uric acid in the identification of COPD patients at an increased risk of adverse outcomes who may need early intensive management.

#### References:

1. Vestbo J, Hurd SS, Agustí AG, et al. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease, GOLD executive summary. *Am J Respir Crit Care Med* 2013; 187: 347–365.
2. Soler-Cataluña JJ, Martínez-García MA, Román-Sánchez P, et al. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. *Thorax* 2005; 60: 925–931.
3. Fox IH. Metabolic basis for disorders of purine nucleotide degradation. *Metabolism* 1981; 30: 616–634.
4. Elsayed NM, Nakashima JM, Postlethwait EM. Measurement of uric acid as a marker of oxygen tension in the lung. *Arch Biochem Biophys* 1993; 302: 228–232.
5. Ruggiero C, Cherubini A, Ble A, et al. Uric acid and inflammatory markers. *Eur Heart J* 2006; 27: 1174–1181.
6. Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. *N Engl J Med* 2008; 359: 1811–1821.
7. Saito H, Nishimura M, Shibuya E, et al. Tissue hypoxia in sleep apnea syndrome assessed by uric acid and adenosine. *Chest* 2002; 122: 1686–1694.
8. Voelkel MA, Wynne KM, Badesch DB, et al. Hyperuricemia in severe pulmonary hypertension. *Chest* 2000; 117:19–24.
9. Aida Y, Shibata Y, Osaka D, et al. The relationship between serum uric acid and spirometric values in participants in a health check: the Takahata study. *Int J Med Sci* 2011; 8: 470–478.
10. Garcia-Pachon E, Padilla-Navas I, Shum C. Serum uric acid to creatinine ratio in patients with chronic obstructive pulmonary disease. *Lung* 2007; 185: 21–24.
11. Choi HK, Liu S, Curhan G. Intake of purine-rich foods, protein, and dairy products and relationship to serum levels of uric acid: The third national health and nutrition examination survey. *Arthritis Rheum.* 2005;52:283-289.
12. Feig DI. Uric acid: A novel mediator and marker of risk in chronic kidney disease?. *Curr Opin Nephrol Hypertens.* 2009;18:526-530.
13. Nyhan WL. Lesch-Nyhan disease. *J Hist Neurosci.* 2005;14:1-10.
14. Cameron JS, Moro F, Simmonds HA. Gout, uric acid and purine metabolism in paediatric nephrology. *Pediatr Nephrol.* 1993;7:105-118.
15. Rathmann W, Haastert B, Icks A, et al. Ten-year change in serum uric acid and its relation to changes in other metabolic risk factors in young black and white adults: The cardia study. *Eur J Epidemiol.* 2007;22:439-445.
16. Mentzer RM Jr, Rubio R, Berne RM. Release of adenosine by hypoxic canine lung tissue and its possible role in pulmonary circulation. *Am J Physiol.* 1975;229:1625-1631.
17. So A, Thorens B. Uric acid transport and disease. *J Clin Invest.* 2010;120:1791-1799.
18. Choi HK, Curhan G. Beer, liquor, and wine consumption and serum uric acid level: The third national health and nutrition examination survey. *Arthritis Rheum.* 2004;51:1023-1029.
19. Mentzer RM Jr, Rubio R, Berne RM. Release of adenosine by hypoxic canine lung tissue and its possible role in pulmonary circulation. *Am J Physiol.* 1975;229:1625-1631

20. So A, Sorens B. Uric acid transport and disease. *J Clin Invest.* 2010;120:1791-1799
21. Choi HK, Curhan G. Beer, liquor, and wine consumption and serum uric acid level: The third national health and nutrition examination survey. *Arthritis Rheum.*2004;51:1023-1029
22. McCord JM, Roy RS, Schaffer SW. Free radicals and myocardial ischemia. The role of xanthine oxidase. *Adv Myocardiol.* 1985;5:183-189.
23. Anker SD, Doehner W, Rauchhaus M. et al. Uric acid and survival in chronic heart failure: Validation and application in metabolic, functional, and hemodynamic staging. *Circulation.*2003;107:1991-1997.
24. Anker SD, Doehner W, Rauchhaus M, et al.Uric acid and survival in chronic heart failure:validation and application in metabolic,functional, and hemodynamic staging.*Circulation* 2003; 107: 1991–1997.
25. Mohanalakshmi T, Kiran BSR, Srikumar R,et al. Evaluation Of Uric Acid Level, A New Biomarker In Patients With MetabolicSyndrome. *Res J Pharm Biol Chem Sci*2016; 7: 2667.
26. Turner R, Wu Y, Li L, et al. UricAcid Oxidation as a Biomarker ofCardiovascular Disease. *Free Radic BiolMed* 2013; 65: S74.
27. Song JU, Hwang J and Ahn JK. Serum uricacid is positively associated with pulmonary function in Korean health screening examinees.*ModRheumatol* 2017; 27: 1057–1065.
28. Kadowaki T, Hamada H, Yokoyama A,et al. Significance of serum uric acid inpatients with chronic respiratory failure treated with non-invasive positive pressureventilation. *Intern Med* 2007; 46: 691–697.
29. Li L, Wan C and Wen F. An unexpectedrole for serum uric acid as a biomarker forseverity of asthma exacerbation. *Asian Pac JAllergy Immunol* 2014; 32: 93–99.
30. Martinon F, Petrilli V, Mayor A. et al. Gout-associated uric acid crystals activate the NALP3 inflammasome. *Nature.* 2006;440:237-241.
31. Didilescu AC, Hanganu SC, Galie N. et al. The role of smoking in changing essential parameters in body homeostasis]. *Pneumologia.* 2009;58:89-94.